Answers are grounded in this paper and cite their sources.
Case report identifies cardiovascular and ocular abnormalities in a canine after ruxolitinib phosphate ingestion, suggesting implications for JAK inhibitor toxicosis.
This case report describes a canine patient that developed cardiovascular and ocular abnormalities following ingestion of ruxolitinib phosphate 1.5% topical cream. The objective of this report is to characterize the exposure history, clinical presentation, diagnostic findings, therapeutic interventions, and to evaluate ruxolitinib phosphate within the context of its pharmacologic class, emphasizing similarities with related veterinary medications. Building on a recently published retrospective study of oclacitinib maleate overdoses, this case highlights shared clinical manifestations of ruxolitinib phosphate overdose and contributes to a broader understanding of JAK inhibitor toxicosis in veterinary medicine.
No takes yet. Share an insight, caveat, or question.
Swanson et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: